Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 20/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 20/20 | 1.00 |
| ▸ | PDE2A | O00408 | 2/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10756287 | 0.98 | PDE3B (0.97) | PDE3BPDE3APDE2AP2RY12 | |
| Water SCHEMBL10762992 | 0.98 | PDE3B (0.97) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10757126 | 0.85 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10757167 | 0.81 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| Hydrochloric Acid SCHEMBL10758727 | 0.80 | PDE3B (0.97) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10756405 | 0.80 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10760956 | 0.79 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10758549 | 0.74 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL10757026 | 0.73 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL32659810 | 0.73 | PDE3B (0.59) | PDE3BPDE3APDE2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | claimed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | claimed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE3B 55/4885PDE3A 49/4885PDE2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.